A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin in Chemotherapy-Naive Patients with Advanced Non-Small-Cell Lung Cancer
Latest Information Update: 17 May 2016
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 13 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan
- 19 Jan 2014 New trial record